Abstract

Background and Aims : Elevated concentrations of lipoprotein(a) (Lp(a)) are directly related to an increased risk of cardiovascular diseases, thus making its determination a crucial factor for clinical diagnosis. However, the lack of global standardisation of current immunoassay-based measuring procedures (MPs) for Lp(a) leads to inconsistent care of patients. The former Lp(a) reference method and the associated WHO-IFCC reference material are no longer available. Recently, it was decided to evolve to a next generation reference measurement system (RMS) with SI-traceability.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call